Alnylam Pharmaceuticals
ALNYALNY · Stock Price
Historical price data
Overview
Alnylam Pharmaceuticals' mission is to harness RNA interference (RNAi) to develop transformative medicines for patients with serious diseases. The company has achieved its goal of building a sustainable, top-tier biopharmaceutical company, with five FDA-approved products generating significant revenue and a deep clinical pipeline. Its strategy, 'Alnylam 2030,' focuses on expanding into prevalent diseases, advancing next-generation platforms, and scaling global commercial and manufacturing operations to serve millions of patients.
Technology Platform
Proprietary RNA interference (RNAi) platform featuring GalNAc-conjugate delivery for hepatic targeting and next-generation IKARIA technology for extrahepatic delivery, enabling specific gene silencing with subcutaneous administration.
Pipeline
73| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Patisiran | Amyloidosis | Phase 3 | |
| Patisiran | Amyloidosis, Familial | Phase 3 | |
| Givosiran + Placebo | Acute Hepatic Porphyria | Phase 3 | |
| Nucresiran + Sterile Normal Saline (0.9% NaCl) | Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | |
| Lumasiran | Primary Hyperoxaluria Type 1 | Phase 3 |
Funding History
4FDA Approved Drugs
4Competitors
Company Timeline
Founded in Cambridge, United States
Series B: $38.0M
IPO — $49.0M
Series C: $68.0M
FDA Approval: GIVLAARI
FDA Approval: OXLUMO